Pleural Effusion with CC DRG Reimbursement & Medicare

DRG 187 covers inpatient admissions for pleural effusion when a Complication or Comorbidity is present, encompassing diagnostic and therapeutic management of clinically significant effusions. Correct assignment to this Diagnosis-Related Group is important because it determines Medicare inpatient payment relative to other pleural effusion groups and reflects expected resource use.

DRG 187 Overview

DRG 187 covers inpatient admissions for pleural effusion with a qualifying Complication or Comorbidity and includes cases where the pleural fluid accumulation requires diagnostic evaluation or therapeutic intervention. This Diagnosis-Related Group captures clinical scenarios such as parapneumonic effusion, heart failure–related effusion with added complexity, or malignant effusion when a Complication or Comorbidity is present. It matters for Medicare payment because classification into this Diagnosis-Related Group influences base payment relative to lower- or higher-severity groups and drives resource use expectations for hospital stays, procedures, and post-acute needs. Accurate documentation and correct coding of the associated Complication or Complications and Comorbidities affect the assigned Diagnosis-Related Group and resulting inpatient reimbursement.

Acute procedural and drainage technique trials: randomized or prospective comparative studies evaluating different methods of pleural fluid management in hospitalized patients with pleural effusion and at least one complication or comorbidity (for example, comparing large-bore tube thoracostomy versus image-guided small-bore catheter drainage, or bedside ultrasound-guided thoracentesis protocols). These studies enroll acutely ill inpatients—often elderly patients with cardiac, renal, or infectious comorbidities—and focus on short-term outcomes such as symptom relief, procedure-related complications (pneumothorax, bleeding), length of stay, and need for repeat interventions. Results inform procedural best practices and resource utilization decisions that directly affect hospital costs and payer reimbursement for DRG 187 cases.
Comparative effectiveness trials of etiologic and adjunctive treatments during the index hospitalization: pragmatic or observational studies comparing medical management strategies for underlying causes of pleural effusion (for example, diuresis strategies in heart-failure–related effusions, antibiotic strategies for parapneumonic effusions, or anticoagulation management in patients with thromboembolic disease-related effusions). These trials typically enroll medically complex inpatients with coexisting CCs and examine outcomes such as resolution of effusion, progression to complicated pleural infection, ICU transfer, hospital readmission, and total inpatient costs. Findings are relevant to clinicians and payers because they help identify which inpatient treatment pathways reduce complications, shorten length of stay, and lower overall DRG-attributed expenditures.
Post-discharge outcomes and care-coordination studies: observational cohorts or interventional studies testing transitions-of-care interventions (such as early outpatient follow-up, home health nursing, or remote monitoring of symptoms and weight) for patients discharged after hospitalization for pleural effusion with comorbid conditions. These studies follow patients after discharge to measure readmission rates, emergency department returns, functional status, and downstream costs over 30–90 days, often stratified by comorbidity burden and index-procedure type. This research area is important to providers and payers because reducing preventable readmissions and identifying patients who benefit from targeted outpatient services can improve quality metrics and decrease total costs associated with DRG 187.

Acute procedural and drainage technique trials: randomized or prospective comparative studies evaluating different methods of pleural fluid management in hospitalized patients with pleural effusion and at least one complication or comorbidity (for example, comparing large-bore tube thoracostomy versus image-guided small-bore catheter drainage, or bedside ultrasound-guided thoracentesis protocols). These studies enroll acutely ill inpatients—often elderly patients with cardiac, renal, or infectious comorbidities—and focus on short-term outcomes such as symptom relief, procedure-related complications (pneumothorax, bleeding), length of stay, and need for repeat interventions. Results inform procedural best practices and resource utilization decisions that directly affect hospital costs and payer reimbursement for DRG 187 cases.
Comparative effectiveness trials of etiologic and adjunctive treatments during the index hospitalization: pragmatic or observational studies comparing medical management strategies for underlying causes of pleural effusion (for example, diuresis strategies in heart-failure–related effusions, antibiotic strategies for parapneumonic effusions, or anticoagulation management in patients with thromboembolic disease-related effusions). These trials typically enroll medically complex inpatients with coexisting CCs and examine outcomes such as resolution of effusion, progression to complicated pleural infection, ICU transfer, hospital readmission, and total inpatient costs. Findings are relevant to clinicians and payers because they help identify which inpatient treatment pathways reduce complications, shorten length of stay, and lower overall DRG-attributed expenditures.
Post-discharge outcomes and care-coordination studies: observational cohorts or interventional studies testing transitions-of-care interventions (such as early outpatient follow-up, home health nursing, or remote monitoring of symptoms and weight) for patients discharged after hospitalization for pleural effusion with comorbid conditions. These studies follow patients after discharge to measure readmission rates, emergency department returns, functional status, and downstream costs over 30–90 days, often stratified by comorbidity burden and index-procedure type. This research area is important to providers and payers because reducing preventable readmissions and identifying patients who benefit from targeted outpatient services can improve quality metrics and decrease total costs associated with DRG 187.

OpenPayer

Summary & Overview

Pleural Effusion with CC: Inpatient Reimbursement Overview

DRG 187 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes